Individualized Dosing Reduces Niraparib-Related TEAEs in Ovarian Cancer Maintenance
March 17th 2019
Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.